Despite many guidelines set out by several committees programmes for screening the cholesterol concentrations of the population and subsequent treatment of people with high concentrations remain controversial. Recommendations range from no screening to screening all adults before age 30.1 The definition of high risk groups for selective screening varies and has not been examined systematically. 2 Failure to distinguish between relative and absolute risks and benefits in some guidelines may have resulted in inappropriate recommendations.
We quantified the potential benefits of a programme for screening the population of England and Wales in terms ofpreventing deaths from coronary heart disease.
Methods
We used data from the Office of Population Censuses and Surveys for England and Wales in 1985 that were stratified by sex and age' to calculate the expected numbers of deaths from coronary heart disease over five years. We assumed that they had been screened and that drugs had been prescribed over five years for all people with concentrations -6 5 mmol/l, and that compliance was 100%. We used prevalences of cholesterol concentrations -6 5 mmol/I obtained from the Scottish Monica survey4 and relative risks approximated from prospective studies5 to estimate the number of deaths from coronary heart disease over five years in people with cholesterol concentrations -6 5 mmolUl. We then calculated the number of deaths that would have been prevented if all people with such concentrations had been treated, assuming a 20% reduction in mortality from coronary heart disease in all age and sex groups.
We then derived prevalences of cholesterol concentrations : 6-5 mmol/l specific to age and sex assuming that the mean cholesterol concentration in the population was decreased by 0 5 mmol/1,3 and, assuming that mortality was the same in people with each cholesterol concentration, estimated the potential reduction in numbers of deaths from coronary heart disease with these prevalences. for all three doses of vaccine and four for the second and third doses); the other departments used standard doses intramuscularly. The intradermal route is effective34 but is the subject of debate,5 and the product licence for hepatitis B vaccine is for only the intramuscular route. An alternative way in which districts may save money is by asking staff to get their general practitioners to prescribe the vaccine, so that costs are transferred to family practitioner committees' budgets. This, however, introduces an unnecessary hurdle for staff, which is likely to decrease take up. Family practitioner committees' budgets financed (or were planned to finance) 80% or more of the immunisations in five districts and a mean of 18% in a further-eight districts. This is a pragmatic solution for districts striving to keep within budgets but is a false economy for the NHS, which loses discounts of about 25% that are available to districts buying in bulk. These problems are unlikely to be resolved unless district health authorities and family practitioner committees are merged and given a common budget.
The financial constraints on the districts are unlikely to absolve them from their legal responsibilities to protect their workforce against hazards at work under the Health and Safety at Work Act (1974) and the Control of Substances Hazardous to Health Regulations, which are soon to be introduced.
